Clinical utility of combined assessments of 4D volumetric perfusion CT, diffusion-weighted MRI and
Humans
Squamous Cell Carcinoma of Head and Neck
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Fluorodeoxyglucose F18
Carcinoma, Squamous Cell
/ diagnostic imaging
Positron-Emission Tomography
/ methods
Diffusion Magnetic Resonance Imaging
/ methods
Chemoradiotherapy
/ methods
Four-Dimensional Computed Tomography
Head and Neck Neoplasms
/ diagnostic imaging
Perfusion
Radiopharmaceuticals
Chemoradiotherapy
Head and neck cancer
Multiparametric imaging
Perfusion CT
Prognostic prediction
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
06 Feb 2023
06 Feb 2023
Historique:
received:
27
03
2022
accepted:
07
01
2023
entrez:
7
2
2023
pubmed:
8
2
2023
medline:
9
2
2023
Statut:
epublish
Résumé
Multiparametric imaging has been seen as a route to improved prediction of chemoradiotherapy treatment outcomes. Four-dimensional volumetric perfusion CT (4D PCT) is useful for whole-organ perfusion measurement, as it reflects the heterogeneity of the tumor and its perfusion parameters. However, there has been no study using multiparametric imaging including 4D PCT for the prognostic prediction of chemoradiotherapy. The purpose of this study was to determine whether combining assessments of 4D PCT with diffusion-weighted MRI (DWI) and We examined 53 patients with HNSCC who underwent 4D PCT, DWI and PET-CT before chemoradiotherapy. The imaging and clinical parameters were assessed the relations to locoregional control (LRC) and progression-free survival (PFS) by logistic regression analyses. A receiver operating characteristic (ROC) analysis was performed to assess the accuracy of the significant parameters identified by the multivariate analysis for the prediction of LRC and PFS. We additionally assessed using the scoring system whether these independent parameters could have a complementary role for the prognostic prediction. The median follow-up was 30 months. In multivariate analysis, blood flow (BF; p = 0.02) and blood volume (BV; p = 0.04) were significant prognostic factors for LRC, and BF (p = 0.03) and skewness of the ADC histogram (p = 0.02) were significant prognostic factors for PFS. A significant positive correlation was found between BF and BV (ρ = 0.6, p < 0.001) and between BF and skewness (ρ = 0.46, p < 0.01). The ROC analysis showed that prognostic accuracy for LRC of BF, BV, and combination of BF and BV were 77.8%, 70%, and 92.9%, and that for PFS of BF, skewness, and combination of BF and skewness were 55.6%, 63.2%, and 77.5%, respectively. The scoring system demonstrated that the combination of higher BF and higher BV was significantly associated with better LRC (p = 0.04), and the combination of lower BF and lower skewness was significantly associated with worse PFS (p = 0.004). A combination of parameters derived from 4DPCT and ADC histograms may enhance prognostic accuracy in HNSCC patients treated with chemoradiotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Multiparametric imaging has been seen as a route to improved prediction of chemoradiotherapy treatment outcomes. Four-dimensional volumetric perfusion CT (4D PCT) is useful for whole-organ perfusion measurement, as it reflects the heterogeneity of the tumor and its perfusion parameters. However, there has been no study using multiparametric imaging including 4D PCT for the prognostic prediction of chemoradiotherapy. The purpose of this study was to determine whether combining assessments of 4D PCT with diffusion-weighted MRI (DWI) and
METHODS
METHODS
We examined 53 patients with HNSCC who underwent 4D PCT, DWI and PET-CT before chemoradiotherapy. The imaging and clinical parameters were assessed the relations to locoregional control (LRC) and progression-free survival (PFS) by logistic regression analyses. A receiver operating characteristic (ROC) analysis was performed to assess the accuracy of the significant parameters identified by the multivariate analysis for the prediction of LRC and PFS. We additionally assessed using the scoring system whether these independent parameters could have a complementary role for the prognostic prediction.
RESULTS
RESULTS
The median follow-up was 30 months. In multivariate analysis, blood flow (BF; p = 0.02) and blood volume (BV; p = 0.04) were significant prognostic factors for LRC, and BF (p = 0.03) and skewness of the ADC histogram (p = 0.02) were significant prognostic factors for PFS. A significant positive correlation was found between BF and BV (ρ = 0.6, p < 0.001) and between BF and skewness (ρ = 0.46, p < 0.01). The ROC analysis showed that prognostic accuracy for LRC of BF, BV, and combination of BF and BV were 77.8%, 70%, and 92.9%, and that for PFS of BF, skewness, and combination of BF and skewness were 55.6%, 63.2%, and 77.5%, respectively. The scoring system demonstrated that the combination of higher BF and higher BV was significantly associated with better LRC (p = 0.04), and the combination of lower BF and lower skewness was significantly associated with worse PFS (p = 0.004).
CONCLUSION
CONCLUSIONS
A combination of parameters derived from 4DPCT and ADC histograms may enhance prognostic accuracy in HNSCC patients treated with chemoradiotherapy.
Identifiants
pubmed: 36747228
doi: 10.1186/s13014-023-02202-x
pii: 10.1186/s13014-023-02202-x
pmc: PMC9901150
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Informations de copyright
© 2023. The Author(s).
Références
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2122-2138
pubmed: 29948105
AJR Am J Roentgenol. 2018 Nov;211(5):1106-1111
pubmed: 30240295
Clin Cancer Res. 2009 Feb 1;15(3):986-94
pubmed: 19188170
Invest Radiol. 2010 Jul;45(7):419-26
pubmed: 20498611
Radiology. 2013 Feb;266(2):531-8
pubmed: 23151830
AJNR Am J Neuroradiol. 2010 Mar;31(3):576-81
pubmed: 19875471
Strahlenther Onkol. 2001 Sep;177(9):469-73
pubmed: 11591020
Radiology. 2009 May;251(2):422-8
pubmed: 19276321
Oncotarget. 2017 Mar 17;8(33):55600-55612
pubmed: 28903447
AJR Am J Roentgenol. 2013 Jan;200(1):35-43
pubmed: 23255739
Head Neck. 2013 Jan;35(1):15-22
pubmed: 22307893
Eur J Radiol. 2014 Mar;83(3):537-44
pubmed: 24387935
In Vivo. 2018 Sep-Oct;32(5):1193-1198
pubmed: 30150443
Invest Radiol. 1986 Sep;21(9):720-33
pubmed: 3095258
Br J Cancer. 2014 Dec 9;111(12):2205-13
pubmed: 25268373
Oral Oncol. 2019 Jan;88:75-83
pubmed: 30616800
Radiother Oncol. 2020 Sep;150:128-135
pubmed: 32544609
AJNR Am J Neuroradiol. 2007 Feb;28(2):328-34
pubmed: 17297007
Eur J Radiol. 2012 Oct;81(10):2853-9
pubmed: 21794997
Transl Oncol. 2018 Apr;11(2):498-503
pubmed: 29510360
Cancers (Basel). 2022 Jan 03;14(1):
pubmed: 35008380
Eur J Radiol Open. 2015 Mar 17;2:46-54
pubmed: 26937435
AJNR Am J Neuroradiol. 2011 Aug;32(7):1195-201
pubmed: 21757530
J Clin Oncol. 2006 Jul 10;24(20):3293-8
pubmed: 16829653
AJR Am J Roentgenol. 2014 Apr;202(4):851-8
pubmed: 24660716
Int J Radiat Oncol Biol Phys. 1988 May;14(5):831-8
pubmed: 3360652
Cancer Imaging. 2016 Aug 19;16(1):23
pubmed: 27542718
Radiology. 2010 Aug;256(2):348-64
pubmed: 20656830
AJR Am J Roentgenol. 2013 Jun;200(6):W603-9
pubmed: 23701090
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):299-307
pubmed: 21236594
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1351-6
pubmed: 14630273
PLoS One. 2014 Dec 22;9(12):e115933
pubmed: 25531391
Cancer. 1997 Jan 15;79(2):220-5
pubmed: 9010094
Oncotarget. 2017 Mar 4;8(37):62606-62621
pubmed: 28977973